Oxygen-Free Days as an Outcome Measure in Clinical Trials of Therapies for COVID-19 and Other Causes of New-Onset Hypoxemia

Document Details

Document Type
Pub Defense Publication
Publication Date
Oct 01, 2022
Source ID
10.1016/j.chest.2022.04.145

Entities

People

  • Adit A. Ginde
  • Ari Moskowitz
  • B. Taylor Thompson
  • Christopher J. Lindsell
  • D. Clark Files
  • David J. Douin
  • Eileen Rubin
  • Gordon R. Bernard
  • James Troendle
  • Kevin W Gibbs
  • Kristin Hudock
  • Li Wang
  • Lisa H. Merck
  • Marjolein De Wit
  • Matthew S. Shotwell
  • Matthew W. Semler
  • Meghan Morrison Joly
  • Michelle Harkins
  • Michelle N. Gong
  • Samuel M Brown
  • Sean P. Collins
  • Wesley H. Self
  • Yves Rosenberg

Organizations

  • AbbVie
  • Arog Pharmaceuticals (United States)
  • Centers for Disease Control and Prevention
  • National Center for Advancing Translational Sciences
  • National Heart, Lung, and Blood Institute
  • National Institute of General Medical Sciences
  • National Institutes of Health
  • United States Department of Defense
  • University of Wisconsin–Madison
  • Vanderbilt University Medical Center